SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-009567
Filing Date
2024-06-28
Accepted
2024-06-27 17:32:24
Documents
14
Period of Report
2024-06-27
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20240627x8k.htm   iXBRL 8-K 62509
2 EX-10.1 plx-20240627xex10d1.htm EX-10.1 621078
  Complete submission text file 0001558370-24-009567.txt   869696

Data Files

Seq Description Document Type Size
3 EX-101.SCH plx-20240627.xsd EX-101.SCH 3479
4 EX-101.LAB plx-20240627_lab.xml EX-101.LAB 16016
5 EX-101.PRE plx-20240627_pre.xml EX-101.PRE 10761
17 EXTRACTED XBRL INSTANCE DOCUMENT plx-20240627x8k_htm.xml XML 4864
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 241080634
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)